Based on these observations, Teppert and coworkers have developed a double-targeting immunotherapy combining CAR and TCR technologies: CAR’TCR-T cells, co-expressing CD33-CAR and a transgenic dNPM1-TCR, showed potent and prolonged anti-tumor activity against NPM1-mutant AMLs [151]. Here, CD33 is linked to neoplasm.